{"changeSha256":"37233f63fe68454eb73e7c56f2ebc578d6f2c947ae42d63f48ccc311e452454c","changedAt":"2026-11-14","changedFields":[{"after":"FDA-approved as Forzinity under accelerated approval for Barth syndrome","before":"U.S. accelerated approval for a specified Barth syndrome population","field":"Status"},{"after":"A mitochondria-targeting peptide that FDA granted accelerated approval as Forzinity to improve muscle strength in people with Barth syndrome weighing at least 30 kg.","before":"FDA granted Forzinity (elamipretide) accelerated approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg.","field":"Profile summary"},{"after":"The approval rests on muscle-strength increases seen in the open-label extension of a 12-person trial that missed its main goals. FDA requires a randomized confirmatory trial and may withdraw the approval if benefit is not verified.","before":"FDA's September 19, 2025 approval letter requires a confirmatory trial to verify clinical benefit. The approval concerns this product and specified use; a recruiting trial record does not describe its full regulatory status.","field":"Evidence note"},{"after":"ctg-nct07531251-v4, fda-forzinity-approval-2025, fda-forzinity-label-2025, federal-register-2024-20062-66035b025ae4","before":"ctg-nct07531251-v4, fda-forzinity-approval-2025, fda-forzinity-label-2025","field":"Cited source records"},{"after":"Stealth BioTherapeutics Inc. [sources: ctg-nct07531251-v4]; U.S. Food and Drug Administration [sources: fda-forzinity-approval-2025]","before":"Stealth BioTherapeutics Inc. [sources: ctg-nct07531251-v4]","field":"Named organizations"},{"after":"name: ctg-nct07531251-v4; aliases: ctg-nct07531251-v4, fda-forzinity-approval-2025; category: ctg-nct07531251-v4; status: fda-forzinity-approval-2025, fda-forzinity-label-2025; summary: fda-forzinity-approval-2025, fda-forzinity-label-2025; evidenceNote: fda-forzinity-label-2025, fda-forzinity-approval-2025","before":"name: ctg-nct07531251-v4; aliases: ctg-nct07531251-v4, fda-forzinity-approval-2025; category: ctg-nct07531251-v4; status: fda-forzinity-approval-2025; summary: fda-forzinity-approval-2025; evidenceNote: fda-forzinity-approval-2025","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/elamipretide/versions/5/","version":5},"id":"profile:elamipretide:v5","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers drawn from the Forzinity prescribing information and FDA’s accelerated approval letter, and added the Federal Register notice of the 2024 advisory committee meeting.","peptideSlugs":["elamipretide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/elamipretide/v4.json","sha256":"8c1071a5036b1b3bab408d5845b0f07b35e8c1f18345dea7bb21169a4fbdec8c"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/elamipretide/versions/4/","version":4},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-forzinity-label-2025","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FORZINITY, revised September 2025: U.S. prescribing information","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf","verifiedAt":"2026-09-15"},{"id":"fda-forzinity-approval-2025","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"Forzinity (elamipretide): NDA 215244 accelerated approval letter, September 19, 2025","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215244Orig1s000Approv.pdf","verifiedAt":"2026-09-15"}],"subject":{"slug":"elamipretide","type":"profile"}}
